Harnessing the U.S. Taxpayer to Fight Cancer and Make Profits

Enthusiasm for cancer immunotherapy is soaring, price and so is Arie Belldegrun’s fortune.

Dr. Belldegrun, order a physician, co-founded Kite Pharma, a company that could be the first to market next year with a highly anticipated new immunotherapy treatment. But even without a product, Dr. Belldegrun has struck gold.

His stock in Kite is worth about $170 million. Investors have profited along with him, as the company’s share price has soared to about $50 from an initial price of $17 in 2014.

Read Full Article Here >>